PL437046A1 - Serum arsenic, zinc and selenium concentration as a marker of survival in patients with prostate cancer in Poland - Google Patents

Serum arsenic, zinc and selenium concentration as a marker of survival in patients with prostate cancer in Poland

Info

Publication number
PL437046A1
PL437046A1 PL437046A PL43704621A PL437046A1 PL 437046 A1 PL437046 A1 PL 437046A1 PL 437046 A PL437046 A PL 437046A PL 43704621 A PL43704621 A PL 43704621A PL 437046 A1 PL437046 A1 PL 437046A1
Authority
PL
Poland
Prior art keywords
serum
arsenic
prostate cancer
poland
survival
Prior art date
Application number
PL437046A
Other languages
Polish (pl)
Inventor
Jan LUBIŃSKI
Cezary Cybulski
Jacek Gronwald
Tomasz Huzarski
Katarzyna Białkowska
Róża Derkacz
Wojciech MARCINIAK
Anna Jakubowska
Original Assignee
Read-Gene Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Read-Gene Spółka Akcyjna filed Critical Read-Gene Spółka Akcyjna
Priority to PL437046A priority Critical patent/PL437046A1/en
Publication of PL437046A1 publication Critical patent/PL437046A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Przedmiotem zgłoszenia jest sposób określenia ryzyka zgonu u mężczyzn z rakiem prostaty, charakteryzujący się tym, że obejmuje ilościową ocenę stężenia arsenu w surowicy osoby badanej, przy czym stężenie wskazuje na blisko 5 krotnie zmniejszone ryzyko zgonu w stosunku do ćwiartki ze stężeniem arsenu w surowicy ≤ 0,72 µg/l, w przypadku występowania wartości stężenia arsenu w surowicy w przedziale 0,73 - 0,82 µg/l.The subject of the report is a method of determining the risk of death in men with prostate cancer, characterized by the fact that it includes the quantification of the arsenic concentration in the serum of the tested person, the concentration indicating an almost 5-fold reduced risk of death in relation to the quarter with the serum arsenic concentration ≤ 0 72 µg / l if serum arsenic values are within the range of 0.73 - 0.82 µg / l.

PL437046A 2021-02-18 2021-02-18 Serum arsenic, zinc and selenium concentration as a marker of survival in patients with prostate cancer in Poland PL437046A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL437046A PL437046A1 (en) 2021-02-18 2021-02-18 Serum arsenic, zinc and selenium concentration as a marker of survival in patients with prostate cancer in Poland

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL437046A PL437046A1 (en) 2021-02-18 2021-02-18 Serum arsenic, zinc and selenium concentration as a marker of survival in patients with prostate cancer in Poland

Publications (1)

Publication Number Publication Date
PL437046A1 true PL437046A1 (en) 2022-08-22

Family

ID=83723860

Family Applications (1)

Application Number Title Priority Date Filing Date
PL437046A PL437046A1 (en) 2021-02-18 2021-02-18 Serum arsenic, zinc and selenium concentration as a marker of survival in patients with prostate cancer in Poland

Country Status (1)

Country Link
PL (1) PL437046A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL446712A1 (en) * 2023-11-13 2025-05-19 Read-Gene Spółka Akcyjna Correlation between serum selenium and zinc concentrations as a prognostic marker in patients with prostate cancer
PL448864A1 (en) * 2024-06-17 2025-12-22 Read-Gene Spółka Akcyjna Selenium and zinc concentration in biological material as a marker of survival in patients with kidney cancer in Poland
PL449871A1 (en) * 2024-09-20 2026-03-23 Read-Gene Spółka Akcyjna Copper-to-zinc ratio in serum as a biomarker of survival in patients with prostate cancer

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL446712A1 (en) * 2023-11-13 2025-05-19 Read-Gene Spółka Akcyjna Correlation between serum selenium and zinc concentrations as a prognostic marker in patients with prostate cancer
PL448864A1 (en) * 2024-06-17 2025-12-22 Read-Gene Spółka Akcyjna Selenium and zinc concentration in biological material as a marker of survival in patients with kidney cancer in Poland
PL449871A1 (en) * 2024-09-20 2026-03-23 Read-Gene Spółka Akcyjna Copper-to-zinc ratio in serum as a biomarker of survival in patients with prostate cancer

Similar Documents

Publication Publication Date Title
PL440972A1 (en) Method of determining the risk of cancer in women depending on the ratio of selenium to arsenic concentrations in blood
Barnadas et al. Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study)
DE602005014104D1 (en) METHOD FOR DETERMINING THE PRESENCE OR QUANTITY OF SILVER-MARKED SAMPLES
Prater et al. Incidence of metachronous contralateral breast cancer in the Canton of Zurich: a population-based study of the cancer registry
PL436999A1 (en) Serum copper concentration as a prognostic marker in patients with prostate cancer in Poland
Humann-Ziehank et al. Long-term study of ovine pulmonary adenocarcinogenesis in sheep with marginal vs. sufficient nutritional selenium supply: results from computed tomography, pathology, immunohistochemistry, JSRV-PCR and lung biochemistry
PL439315A1 (en) The method of determining the risk of cancer in women depending on the concentration of selenium in the blood
PL439316A1 (en) How to determine the risk of cancer in women according to the concentration of zinc in the blood
PL434767A1 (en) Concentration of zinc in serum as a prognostic marker in persons with breast cancer in Poland
PL446712A1 (en) Correlation between serum selenium and zinc concentrations as a prognostic marker in patients with prostate cancer
WO2019194862A3 (en) Radioprotectors and electron paramagnetic resonance for determination of cellular resistance to ionizing radiation without radiation exposure
PL433150A1 (en) Method for determining the risk of cancers in women with BRCA1 mutations, depending on blood lead level
PL438655A1 (en) Method of determining the risk of cancer in women depending on concentration of lead in the blood
PL439313A1 (en) Method for determining the risk of cancers in women, depending on concentration of arsenic in the blood
PL437896A1 (en) Way to determine the risk of cancer in men according to the concentration of arsenic in the blood
PL417957A1 (en) Method for determining the risk of prostatic carcinoma
Jain et al. Hepatocellular carcinoma arising in a testicular teratoma: a distinct and unrecognized secondary somatic malignancy
PL437608A1 (en) Method of determining the risk of cancer in women according to the concentration of cadmium in the blood
PL437895A1 (en) Way to determine the risk of cancer in men according to the concentration of copper in the blood
이태우 et al. The effects of exposure to lead, cadmium and mercury on follicle-stimulating hormone levels in men and postmenopausal women: data from the Second Korean National Environmental Health Survey (2012–2014)
PL439317A1 (en) Method for determining the risk of cancers in women, depending on concentration of arsenic in the blood of women who are carriers of the most common BRCA1 and BRCA2 gene mutations
PL438563A1 (en) Serum selenium concentration as a marker of survival in patients with malignant melanoma in Poland
PL438040A1 (en) Serum manganese concentration as a prognostic marker in patients with breast cancer
PL441999A1 (en) Method of determining the risk of cancer in men depending on the ratio of concentrations of selected elements in the blood
PL437899A1 (en) Way to determine the risk of cancer in men according to the concentration of lead in the blood